- Viewpoint is focused on solidifying a global [212Pb] supply strategy through relationship building from research through commercialization
- Agreement significantly expands Company's network of researchers and clinicians in the UK and Europe
CORALVILLE, IA / ACCESSWIRE / November 16, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into a Memorandum of Understanding (MoU) with The National Nuclear Laboratory (NNL) to explore avenues to supply Pb-212 to researchers, and possibly clinicians, in the United Kingdom and Europe, using Viewpoint's proprietary isotope generator, VMT-𝛼-GEN.
VMT-𝛼-GEN is an elegantly-designed isotope generator that provides therapeutic doses of Pb-212 for the Company's therapeutics - part of its ("Theranostic") programs for the treatment of cancers (including metastatic melanoma, neuroendocrine tumors, and other oncology indications in the company pipeline).
"This agreement is great news for the UK nuclear medicine research community and ultimately, cancer patients. Targeted radionuclide therapy with alpha-emitting radionuclides such as actinium-225 has shown some astonishing success in early small-scale trials for treating cancer patients recently, but availability of these radionuclides is a major roadblock to implementing it more widely, particularly in the UK. The availability of lead-212 made possible by this collaboration will go a long way to removing this roadblock, allowing the UK's world-leading radiochemistry, radiobiology and clinical researchers to develop new treatments for cancer," added Phil Blower, DPhil, FRSC, Professor of Imaging Chemistry, KCL, Head of Dept of Imaging Chemistry and Biology.
The National Nuclear Laboratory is a UK government owned and operated nuclear services technology provider covering the whole of the nuclear fuel cycle. As part of the agreement, Viewpoint and NNL will explore opportunities for the provision of feedstock radionuclides at the appropriate specification for production of VMT-α-GEN generators; and the use of laboratory facilities required for the production of generators in the UK.
"This agreement with NNL is a momentous step forward as we work to deploy our proprietary VMT-𝛼-GEN generator and thereby expand the global availability of lead-212. We believe our VMT-𝛼-GEN holds a tremendous amount of potential and this collaboration enables us to supply lead-212 to support preclinical work and clinical trials utilizing VMT-α-GEN in the United Kingdom," commented Michael K. Schultz, PhD, Chief Science Officer of Viewpoint. "We are committed to bolstering our networks with researchers as well as distribution in the UK and Europe to optimize that potential. We are honored to be working with the NNL team and look forward to leveraging their knowledge and expertise."
Radionuclide generators such as VMT-𝛼-GEN are used commonly in radiopharmaceutical manufacturing operations and nuclear medicine facilities across the world. The devices share a common characteristic of enabling the production of a purified chemical form of the radionuclide needed that can be easily combined with ligands that seek out cancerous tumors. Because the shelf life of VMT-𝛼-GEN is based on longer-lived radionuclides, a single shipment of VMT-𝛼-GEN can be used to produce radiopharmaceutical doses daily, for up to a week or more. Given their small footprint, multiple generators can easily be operated within a single facility simultaneously. The device also simplifies radioactive waste management as the spent generator can be easily returned to the manufacturer in approved packaging to eliminate radioactive waste from the medical center or radiopharmacy.
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company's proprietary technology utilizes lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach allows the specific tumor to be recognized and precisely treated; this approach has the potential to improve efficacy and potentially minimize the toxicity associated with other types of cancer treatments.
The Company's Melanoma (VMT01) and Neuroendocrine Tumor (VMT-𝛼-NET) Programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations.
For more information, please visit the Company's website viewpointmt.com.
Chief Executive Officer
JTC Team, LLC
SOURCE: Viewpoint Molecular Targeting, Inc.
View source version on accesswire.com: